Zerlasiran

Zerlasiran liver targeting subunit
Clinical data
Other namesSLN360
Identifiers
  • N-[(2R,3R,4R,5R,6R)-2-[4-[3-[2,2-bis[3-[4-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutoxy-hydroxyphosphinothioyl]oxypropoxymethyl]-3-[6-[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyhexoxy]propoxy]propoxy-hydroxyphosphinothioyl]oxybutoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
UNII
Chemical and physical data
FormulaC66H122N6O38P4S4
Molar mass1859.84 g·mol−1

Zerlasiran is an investigational new drug that is being evaluated to treat atherosclerotic cardiovascular disease. It is small interfering RNA (siRNA) drug candidate designed to reduce levels of lipoprotein(a).

References

  1. 1 2 De Los Reyes C, Rikhi RR, Doherty S, Hernandez S, Mirzai S, Shapiro MD, et al. (December 2025). "Current Clinical Trials for Treating Elevated Lipoprotein(a)". Current Cardiovascular Risk Reports. 19 (1) 7. doi:10.1007/s12170-025-00759-8. PMC 12282488. PMID 40703143.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 129" (PDF). WHO Drug Information. 36 (2). World Health Organization: 533. 2024. Retrieved 30 September 2025.[dead link]
  3. ↑ WO 2023152194, Rider D, Swerdlow D, Campion G, Scrimgeour A, Rambaran C, Wilson R, Machacek M, Schulthess P, Wade J, "Compositions and methods for reducing apolipoprotein(a) expression", published 2023-08-17, assigned to Silence Therapeutics GmbH